Please assess the completion status of the following clinical trial:

Trial Title: Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Males or females of any age with documented positive RT-PCR in blood for acute Ebola virus infection within 3 days prior to enrollment and who have symptoms of any duration.~* Willingness of study participant to accept randomization to any assigned treatment arm.~* All males and females of childbearing potential must be willing to use effective methods of contraception, from time of enrollment until Day 58 of study.~* Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study.~* Ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so.~EXCLUSION CRITIERA:~* Patients who, in the judgment of the investigator, will be unlikely or unable to comply with the requirements of this protocol through Day 28.~* Prior treatment with any investigational antiviral drug therapy against Ebola virus infection within 5 half-lives or 30 days, whichever is longer, prior to enrollment. (Patients who have received an experimental (or, in future, potentially a licensed) immunization against Ebola virus remain eligible.)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Remdesivir plus optimized Standard of Care (oSOC)
- B (Type: EXPERIMENTAL): MAb114 plus optimized Standard of Care (oSOC)
- C (Type: EXPERIMENTAL): REGN-EB3 plus optimized Standard of Care (oSOC)
- Control (Type: EXPERIMENTAL): Zmapp plus optimized Standard of Care (oSOC)

Based on this trial design, predict the completion outcome and termination type (if applicable).